KR101665146B1 - 인플루엔자 ａ 바이러스 서브타입 ｈ1에 대항하는 호모서브타입 교차 중화 특성을 갖는 모노클로날 항체 - Google Patents

인플루엔자 ａ 바이러스 서브타입 ｈ1에 대항하는 호모서브타입 교차 중화 특성을 갖는 모노클로날 항체 Download PDF

Info

Publication number
KR101665146B1
KR101665146B1 KR1020107029309A KR20107029309A KR101665146B1 KR 101665146 B1 KR101665146 B1 KR 101665146B1 KR 1020107029309 A KR1020107029309 A KR 1020107029309A KR 20107029309 A KR20107029309 A KR 20107029309A KR 101665146 B1 KR101665146 B1 KR 101665146B1
Authority
KR
South Korea
Prior art keywords
influenza
virus
subtype
ser
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020107029309A
Other languages
English (en)
Korean (ko)
Other versions
KR20110020865A (ko
Inventor
로버르토 부리오니
마시모 클레멘티
Original Assignee
포모나 리세르사 에스.알.엘.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40303127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101665146(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 포모나 리세르사 에스.알.엘. filed Critical 포모나 리세르사 에스.알.엘.
Publication of KR20110020865A publication Critical patent/KR20110020865A/ko
Application granted granted Critical
Publication of KR101665146B1 publication Critical patent/KR101665146B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020107029309A 2008-05-27 2009-05-27 인플루엔자 ａ 바이러스 서브타입 ｈ1에 대항하는 호모서브타입 교차 중화 특성을 갖는 모노클로날 항체 Active KR101665146B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITTO2008A000398 2008-05-27
IT000398A ITTO20080398A1 (it) 2008-05-27 2008-05-27 Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
PCT/IB2009/052212 WO2009144667A1 (en) 2008-05-27 2009-05-27 Monoclonal antibodies having homosubtype cross -neutralization properties against influenza a viruses subtype h1

Publications (2)

Publication Number Publication Date
KR20110020865A KR20110020865A (ko) 2011-03-03
KR101665146B1 true KR101665146B1 (ko) 2016-10-11

Family

ID=40303127

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107029309A Active KR101665146B1 (ko) 2008-05-27 2009-05-27 인플루엔자 ａ 바이러스 서브타입 ｈ1에 대항하는 호모서브타입 교차 중화 특성을 갖는 모노클로날 항체

Country Status (17)

Country Link
US (1) US9243054B2 (enExample)
EP (1) EP2294084B2 (enExample)
JP (1) JP5792060B2 (enExample)
KR (1) KR101665146B1 (enExample)
CN (1) CN102124028B (enExample)
AU (1) AU2009252758B2 (enExample)
BR (1) BRPI0912285A2 (enExample)
CA (1) CA2725627C (enExample)
EA (1) EA022855B1 (enExample)
ES (1) ES2555486T5 (enExample)
IL (1) IL209499A (enExample)
IT (1) ITTO20080398A1 (enExample)
MX (1) MX2010012974A (enExample)
NZ (1) NZ590115A (enExample)
SG (1) SG191610A1 (enExample)
WO (1) WO2009144667A1 (enExample)
ZA (1) ZA201009273B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO20070066A1 (it) 2007-01-30 2008-07-31 Pomona Biotechnologies Llc Anticorpi monoclonali anti-idiotipo mimotopi dell'antigene gp 120 di hiv
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
ITTO20080964A1 (it) 2008-12-22 2010-06-23 Natimab Therapeutics S R L Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv
IT1395961B1 (it) * 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
ITTO20110067A1 (it) * 2011-01-26 2012-07-27 Pomona Ricerca Srl Immunoglobuline intere di isotipo igg atte a riconoscere un epitopo di neutralizzazione eterosubtipica sulla regione stelo (stem region) dell'emoagglutinina e loro uso come medicamento antinfluenzale
WO2011117848A1 (en) * 2010-03-26 2011-09-29 Pomona Ricerca S.R.L. Full-length immunoglobulins of the igg isotvpe capable of recognizing a heterosubtvpe neutralizing epitope on the hemagglutinin stem region and their use as anti-influenza medicament
CN102241768B (zh) * 2010-05-14 2013-12-25 中国科学院上海生命科学研究院 一种抗甲型h1n1流感病毒血凝素蛋白的抗体
EP2603237A4 (en) * 2010-08-12 2014-05-21 Theraclone Sciences Inc ANTI-HEMAGGLUTININE ANTIBODY COMPOSITIONS AND METHOD FOR THEIR USE
CN101988050B (zh) * 2010-12-09 2012-06-27 湖南出入境检验检疫局检验检疫技术中心 抗h1n1猪流感病毒血凝素蛋白单克隆抗体，杂交瘤细胞株及抗原捕获elisa试剂盒
RU2457243C1 (ru) * 2011-01-11 2012-07-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт вирусологии им. Д.И. Ивановского" Министерства здравоохранения и социального развития Российской Федерации ШТАММ ГИБРИДНЫХ КУЛЬТИВИРУЕМЫХ КЛЕТОК МЫШИ Mus. Musculus - 1E7, ПРОДУЦИРУЮЩИЙ МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, ИММУНОРЕАКТИВНОЕ С БЕЛКОМ ГЕМАГГЛЮТИНИНА ПАНДЕМИЧЕСКОГО ВИРУСА ГРИППА А/IIV-Moscow/01/09(H1N1)sw1
EP2699688A1 (en) 2011-04-20 2014-02-26 The Trustees Of The University Of Pennsylvania Regimens and compositions for aav-mediated passive immunization of airborne pathogens
WO2013119793A1 (en) * 2012-02-07 2013-08-15 University Of Kansas Chemiluminescent nanoparticles and uses thereof
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
CN113667013B (zh) 2013-10-02 2024-04-09 免疫医疗有限责任公司 中和抗甲型流感抗体及其用途
KR101628331B1 (ko) * 2014-03-28 2016-06-08 주식회사 녹십자엠에스 인플루엔자 a 바이러스 특이적 단클론 항체 및 이를 이용한 인플루엔자 감염 치료 및 진단 방법
ES2833230T3 (es) 2014-05-13 2021-06-14 Univ Pennsylvania Composiciones que comprenden AVV que expresan construcciones y usos de doble anticuerpo del mismo
CA2954780A1 (en) 2014-07-15 2016-01-21 Medimmune, Llc Neutralizing anti-influenza b antibodies and uses thereof
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
EP3307310A2 (en) 2015-05-13 2018-04-18 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-influenza antibodies and methods of use thereof
HUE056407T2 (hu) 2015-06-01 2022-02-28 Medimmune Llc Neutralizáló influenzaellenes kötõmolekulák és alkalmazásaik
US10513553B2 (en) 2015-11-13 2019-12-24 Visterra, Inc. Compositions and methods for treating and preventing influenza
US20190015509A1 (en) 2016-01-13 2019-01-17 Medimmune, Llc Method of treating influenza a
CA3015347A1 (en) 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus
AU2018229293A1 (en) 2017-02-28 2019-08-29 Janssen Biotech, Inc. Influenza vaccines based on AAV vectors
US11827906B2 (en) 2017-02-28 2023-11-28 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) clade f vector and uses therefor
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
KR101972238B1 (ko) * 2017-11-22 2019-04-24 한국생명공학연구원 인플루엔자 a 바이러스 특이적 항체 또는 그의 항원 결합 단편
JP2022521819A (ja) 2019-03-25 2022-04-12 ビステラ， インコーポレイテッド インフルエンザを処置および予防するための組成物および方法
MX2023006444A (es) 2020-12-01 2023-08-10 Univ Pennsylvania Composiciones novedosas con motivos dirigidos a tejido específico y composiciones que los contienen.
WO2022232289A1 (en) 2021-04-27 2022-11-03 Generation Bio Co. Non-viral dna vectors expressing therapeutic antibodies and uses thereof
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use
WO2024243249A1 (en) * 2023-05-23 2024-11-28 The Scripps Research Institute Stabilized hemagglutinin (ha) trimers as influenza vaccine antigens
CN121021682A (zh) * 2025-10-29 2025-11-28 山东第一医科大学(山东省医学科学院) 一种抗甲型h1n1亚型猪流感病毒的重组纳米抗体及其制备方法和应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA836080B (en) 1982-08-23 1984-04-25 Scripps Clinic Res Broad spectrum influenza antisera
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6812024B2 (en) 1987-03-16 2004-11-02 Mcgready Roland Keith Anti-paratopic antibody as an immunogen
US5245015A (en) 1991-04-26 1993-09-14 Tanox Biosystems, Inc. Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro
WO1992015885A1 (en) 1991-03-11 1992-09-17 Idec Pharmaceuticals Corporation Methods for selecting antibody reagents; anti-idiotype antibodies; and aids vaccine formulations
DE69333348T2 (de) 1992-03-09 2004-09-16 San Diego Regional Cancer Center, San Diego Anti-idiotypischer Antikörper und seine Verwendung zur Diagnose und Therapie bei HIV-bezogenen Krankheiten
EP0621339B1 (en) 1992-09-17 2001-10-24 Takara Shuzo Co. Ltd. Immunogenic human influenza A virus haemagglutinin polypeptides
JP3061960B2 (ja) * 1992-09-17 2000-07-10 寳酒造株式会社 抗ヒトインフルエンザウイルス抗体
GB9221654D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
JP2996864B2 (ja) * 1994-03-30 2000-01-11 寳酒造株式会社 抗体可変領域ｄｎａ
US6057421A (en) 1994-11-30 2000-05-02 Immpheron, Inc. Variable heavy and light chain regions of murine monoclonal antibody 1F7
AU5285899A (en) 1998-07-21 2000-02-14 Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh Anti hepatitis c virus antibody and uses thereof
JP2004524829A (ja) 2000-12-01 2004-08-19 アメリカ合衆国 Ｃ型肝炎ウイルスのｅ２糖タンパク質に特異的なモノクローナル抗体、ならびにｃ型肝炎の診断、治療、および予防におけるそれらの使用
FR2817869B1 (fr) 2000-12-07 2005-01-14 Technopharm Anticorps monoclonal humain dirige contre le virus influenza ou un fragment de celui-ci
US6768004B2 (en) 2001-01-11 2004-07-27 Mueller Sybille Nucleotide sequences encoding variable regions of heavy and light chains of monoclonal antibody 1F7, an anti-idiotypic antibody reactive with anti-HIV antibodies
US6964199B2 (en) 2001-11-02 2005-11-15 Cantocor, Inc. Methods and compositions for enhanced protein expression and/or growth of cultured cells using co-transcription of a Bcl2 encoding nucleic acid
WO2003059953A2 (en) 2002-01-17 2003-07-24 Polymun Scientific Immunbiologische Forschung Gmbh Anti-idiotypic antibody inducing hiv-1 neutralizing antibodies
ITRM20020049A1 (it) 2002-01-30 2003-07-30 Biostrands S R L Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
JP2009537147A (ja) 2006-05-15 2009-10-29 シー レーン バイオテクノロジーズ， エルエルシー インフルエンザウイルスに対する中和抗体
EP2059532B1 (en) 2006-09-07 2012-12-26 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2008033159A1 (en) 2006-09-15 2008-03-20 Fraunhofer Usa, Inc. Influenza antibodies, compositions, and related methods
ITTO20070066A1 (it) 2007-01-30 2008-07-31 Pomona Biotechnologies Llc Anticorpi monoclonali anti-idiotipo mimotopi dell'antigene gp 120 di hiv
JP2010538667A (ja) 2007-09-20 2010-12-16 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 新規オリゴクローナル抗体の製造方法
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
ITTO20080964A1 (it) 2008-12-22 2010-06-23 Natimab Therapeutics S R L Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv
IT1395961B1 (it) 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
WO2011117848A1 (en) 2010-03-26 2011-09-29 Pomona Ricerca S.R.L. Full-length immunoglobulins of the igg isotvpe capable of recognizing a heterosubtvpe neutralizing epitope on the hemagglutinin stem region and their use as anti-influenza medicament

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Biochemical and Biophysical Research Communications. Vol. 366, pp. 445-449 (2008)*
Journal of Clinical Microbiology. Vol. 35, No. 5, pp. 1196-1198 (1997)
Journal of General Virology. Vol. 67, No. 6, pp. 983-992 (1986)

Also Published As

Publication number Publication date
EA022855B1 (ru) 2016-03-31
ITTO20080398A1 (it) 2009-11-28
ES2555486T5 (es) 2019-02-15
CA2725627A1 (en) 2009-12-03
CN102124028A (zh) 2011-07-13
US9243054B2 (en) 2016-01-26
CN102124028B (zh) 2015-05-20
EP2294084B2 (en) 2018-09-05
EP2294084B1 (en) 2015-09-09
EP2294084A1 (en) 2011-03-16
AU2009252758B2 (en) 2014-07-31
EA201071365A1 (ru) 2011-08-30
BRPI0912285A2 (pt) 2015-10-20
US20110076265A1 (en) 2011-03-31
SG191610A1 (en) 2013-07-31
ZA201009273B (en) 2012-05-01
CA2725627C (en) 2019-08-06
KR20110020865A (ko) 2011-03-03
JP2011524161A (ja) 2011-09-01
JP5792060B2 (ja) 2015-10-07
NZ590115A (en) 2012-08-31
MX2010012974A (es) 2011-01-21
IL209499A0 (en) 2011-01-31
WO2009144667A1 (en) 2009-12-03
ES2555486T3 (es) 2016-01-04
IL209499A (en) 2016-10-31
AU2009252758A1 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
KR101665146B1 (ko) 인플루엔자 ａ 바이러스 서브타입 ｈ1에 대항하는 호모서브타입 교차 중화 특성을 갖는 모노클로날 항체
KR101605573B1 (ko) 복수의 인플루엔자 바이러스 ａ 서브타입들과 반응할 수 있는 모노클로날 항체
US20120225068A1 (en) Monoclonal antibodies as a medicament for the therapeutic and/or prophylactic treatment of swine-origin influenza a (h1n1) virus (s-oiv) infections
Kalenik et al. Influenza prevention and treatment by passive immunization.
CN110028578B (zh) 广谱抗h7流感病毒的中和性人源单克隆抗体及其应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 10